New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
05:20 EDTINOInovio initiates cervical cancer clinical trial
Inovio Pharmaceuticals announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus-associated cervical cancer. INO-3112 is a combination of Inovio's immunotherapy product, VGX-3100, and its immune activator expressing interleukin-12. VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:09 EDTINOInovio inititates DNA immunotherapy trial for several types of cancer
Subscribe for More Information
December 17, 2014
08:06 EDTINOInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use